Test medicine that blocks hormones for ARVD heart disease
Treatments studied
Part of Genetic & congenital, Heart & circulation clinical trials.
This Phase 2 trial studies whether blocking certain heart/hormone signals can improve ARVD (a heart muscle condition). It also looks at safety by checking how well your kidneys and electrolytes tolerate these medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 18 years old and can give written consent
- You have ARVD confirmed by specific cardiology diagnosis rules
- Your left pumping function (left ventricular ejection fraction) is above 40%
- You are able to take the study medicines and do not have key medication safety problems
- You are not in an excluded situation like pregnancy/lactation or major uncontrolled illness
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how exercise affects heart rhythm in people with ARVC, a genetic heart condition. Participation involves supervised exercise sessions and heart monitoring to better understand safe activity levels.
This trial studies whether a heart medicine called ARNI (sacubitril-valsartan) is safe and works well for people who have a durable LVAD and moderate-to-severe heart pumping weakness. It may help improve symptoms and outcomes, while carefully checking side effects in this higher-risk group.
This trial studies whether a medicine that blocks aldosterone (called an MRA) can improve cardiovascular outcomes in people with high aldosterone levels and high blood pressure. You may be asked to take the study medicine and have blood pressure, heart, and lab tests monitored over time.
This study looks at how mineralocorticoid-related hormone signaling affects small heart blood vessels and how efficiently the heart works in people with high blood pressure. It may help doctors understand which treatments could improve heart function in hypertension.
This trial tests if a common cholesterol medicine, atorvastatin, can slow the progression of arrhythmogenic cardiomyopathy, a genetic heart condition that can cause abnormal heart rhythms. If you have this condition, joining this study may help researchers find a new way to protect your heart.
This trial is testing two heart medications, empagliflozin and ranolazine, to see if they can improve right heart function in people with pulmonary hypertension and right ventricular failure. Participants will monitor their symptoms using a smartphone or tablet.
Hear when a new Arrhythmogenic Right Ventricular Dysplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.